Immunotherapy Efficacy in Viral vs Non-Viral Cancers

Evidence from Virus-Associated Cancers

The American Society of Clinical Oncology notes that phase II studies of anti-PD-1 immunotherapies in nasopharyngeal carcinoma suggest clinical benefit with lower toxicity rates compared to chemotherapy, despite the absence of phase III data 1
Nivolumab achieved a 21% objective response rate with 1-year overall survival of 59% in recurrent/metastatic nasopharyngeal carcinoma, demonstrating meaningful clinical benefit in this EBV-driven malignancy 1
Toripalimab produced a 20.5% objective response rate with median overall survival of 17.4 months in platinum-refractory nasopharyngeal carcinoma, with similar efficacy in PD-L1-positive and PD-L1-negative patients 1
In the pembrolizumab versus chemotherapy trial for recurrent/metastatic head and neck cancer, median overall survival was 17.2 months for pembrolizumab versus 15.3 months for chemotherapy, though this did not reach statistical significance 1
Treatment-related adverse events were substantially lower with pembrolizumab (61.2%) compared to chemotherapy (87.5%), with grade 3-5 toxicity occurring in only 10.3% versus 43.8% 1

Viral cancers often show responses independent of PD-L1 status, with response rates similar in PD-L1-positive and PD-L1-negative patients (27.1% vs 19.1%, P=0.31) 1

Anti-PD-1 monotherapy (pembrolizumab or nivolumab) is the preferred first-line treatment for unresectable or metastatic melanoma due to durable long-term survival benefits, according to the National Comprehensive Cancer Network 2
Extended follow-up of ipilimumab showed long-term survival in approximately 20% of patients (5-year OS 18% vs 9% for dacarbazine) 3
Melanoma responses occur without viral antigen targets, relying instead on high tumor mutational burden and neoantigen expression 3

No biomarker selection is required for anti-PD-1 monotherapy in the metastatic melanoma setting, according to the National Comprehensive Cancer Network 2
Viral antigen expression may override the predictive value of PD-L1 status in determining immunotherapy benefit 1

Consider anti-PD-1 monotherapy as first-line treatment regardless of PD-L1 status for virus-associated cancers, given consistent response rates across biomarker subgroups 1
Expect lower toxicity profiles compared to chemotherapy (grade 3-5 toxicity ~10% vs ~44%) for virus-associated cancers 1
Perform comprehensive biomarker testing including PD-L1, tumor mutational burden, and microsatellite instability status for non-viral cancers 3, 6
Consider combination immunotherapy (ipilimumab/nivolumab) for patients who can tolerate increased toxicity in melanoma, according to the National Comprehensive Cancer Network 2